NCT03577743: Effect of Bevacizumab in Metastatic Triple Negative Breast Cancer

NCT03577743
Breast Cancer Type: Triple Negative
Hormone Mutations:
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Not yet recruiting
Ph+ase 2
Drug Category: Therapeutic Antibody, Tyrosine-Kinase Inhibitor

Key Eligibility Criteria:

Gender: Female
Age: 18 Years to 75 Years (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: 
https://ClinicalTrials.gov/show/NCT03577743

Comments are closed.

Up ↑